LianSn Pharmaceutical, China, was founded in 2003, and headquartered in Beijing. LianSn is a leading pharmaceutical industry group that integrates the entire industry chain of drug innovation, Research & Development, and manufacturing, marketing, and sales of Transdermal Drug Delivery, Oral, Sami solid, and Chinese herbal formulations. • The existing products include; -Oral 12 formulation -5 approvals for TDDS patch formulations -54 approvals for decoction -58 approvals for Chinese herbal drinks Liansheng Pharmaceutical has been rated as a national high-tech enterprise, and actively invests in R&D collaborations with many well-known domestic and overseas research institutes. Obtained 11 national patents, and has obtained 7 international invention patents from the United States and Japan. 1 global first-class new drug is under research. Our focus is cross-border partnering; licensing in /out, acquisition, Co-Discovery/Co-Development, JV, Academic Collaboration, and investment in novel therapies and Research platforms. Please reach out to: asif@liansn.com or my Linkedin to explore more partnership interests.
